In vivo selectivity and localization of reactive oxygen species (ROS) induction by osmium anticancer complexes that circumvent platinum-resistance

Coverdale, James P C; Bridgewater, Hannah E; Song, Ji-Inn; Smith, Nichola A; Barry, Nicolas P E; Bagley, Ian; Sadler, Peter J; Romero Canelon, Isolda

DOI:
10.1021/acs.jmedchem.8b00958

License:
Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Coverdale, JPC, Bridgewater, HE, Song, J-I, Smith, NA, Barry, NPE, Bagley, I, Sadler, PJ & Romero Canelon, I 2018, 'In vivo selectivity and localization of reactive oxygen species (ROS) induction by osmium anticancer complexes that circumvent platinum-resistance', Journal of Medicinal Chemistry, vol. 61, no. 20, pp. 9246–9255. https://doi.org/10.1021/acs.jmedchem.8b00958

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 11. Mar. 2020
In Vivo Selectivity and Localization of Reactive Oxygen Species (ROS) Induction by Osmium Anticancer Complexes That Circumvent Platinum Resistance

James P. C. Coverdale,† Hannah E. Bridgewater,† Ji-Inn Song,† Nichola A. Smith,† Nicolas P. E. Barry,†,‡ Ian Bagley,§ Peter J. Sadler,† and Isolda Romero-Canelón*†,§

†Department of Chemistry, University of Warwick, Coventry CV4 7AL, U.K.
‡School of Chemistry and Biosciences, University of Bradford, Bradford BD7 1DP, U.K.
§BSU Research Technology Platform, University of Warwick, Coventry CV4 7AL, U.K.
¶School of Pharmacy, University of Birmingham, Birmingham B15 2TT, U.K.

ABSTRACT: Platinum drugs are widely used for cancer treatment. Other precious metals are promising, but their clinical progress depends on achieving different mechanisms of action to overcome Pt-resistance. Here, we evaluate 13 organo-Os complexes: 16-electron sulfonyl-diamine catalysts [(η⁶-arene)Os(N,N')] and 18-electron phenylazopyridine complexes [(η⁶-arene)Os(N,N')Cl/II]' (arene = p-cymene, biphenyl, or terphenyl). Their antiproliferative activity does not depend on p21 or p53 status, unlike cisplatin, and their selective potency toward cancer cells involves the generation of reactive oxygen species. Evidence of such a mechanism of action has been found both in vitro and in vivo. This work appears to provide the first study of osmium complexes in the zebrafish model, which has been shown to closely model toxicity in humans. A fluorescent osmium complex, derived from a lead compound, was employed to confirm internalization of the complex, visualize in vivo distribution, and confirm colocalization with reactive oxygen species generated in zebrafish.

INTRODUCTION

Cancer is one of the leading causes of death in the developed world.1,2 As many as half of all cancer chemotherapy regimens include a platinum drug, which typically targets DNA, and is either administered alone or in combination therapies.3 However, both intrinsic and acquired Pt-resistance are major clinical concerns,4–6 requiring the development of drugs that circumvent this problem by possessing an alternative—or multitargeted—mechanism of action (MoA). Other precious metals have promising anticancer activity, including organo-Os (complexes that, unlike cisplatin, do not have DNA as their major target). Specifically, some Os(II) “piano-stool” (metal-arene “half-sandwich”) complexes have been shown to exhibit nanomolar potency against cancer cells7 and yet also low in vivo toxicities.8 The “piano-stool” structure of such complexes allows medicinal chemists to fine-tune the biological properties of the complex by careful manipulation of coordinated ligands, resulting in a wide range of different cellular mechanism(s) of action, not limited to redox modulation (both oxidative and reductive stress),9,10 DNA binding, or protein kinase inhibition.11 Higher oxidation state complexes of osmium also show clinical promise, with potential both in vitro and in vivo.12 The mechanism of action of Os(VI) nitrido complexes developed by Lippard et al. depends greatly on the choice of ligands; structurally similar complexes activate either p53-dependent or p53-independent cell death pathways, depending on the nature of the coordinated ligands.13 We have previously reported two interesting classes of osmium(II) arene anticancer complexes with different chemical properties: osmium—sulfonamide transfer hydrogenation catalysts, which can convert pyruvate to lactate in cells,10 and highly potent osmium-azopyridine complexes, which generate reactive oxygen species (ROS) in cancer cells.7,14 Intrinsic levels of ROS are frequently elevated in cancer cells, typically arising from mitochondrial dysfunction and the higher metabolic activity associated with tumor proliferation and metastasis.15 However, further oxidative stress is known to cause cell cycle arrest and apoptosis,16–19 which therefore presents a novel chemotherapeutic target that could render selectivity toward cancer cells.20 In this work, we compare the antiproliferative activity of these previously reported classes of Os(II) compounds,10,21 their ability to
generate reactive oxygen species (ROS) in both cancer cells and in vivo, as well as their remarkable selectivity and potential for circumventing Pt-resistance.

The 16e Os(II) arene sulfonamide transfer hydrogenation catalysts 1–8 can convert pyruvate to lactate in cells. The highly potent 18e azopyridine complexes are much less reactive (especially the relatively inert iodido complexes) and appear to be activated inside cells and target mitochondria (Supporting Information). Complex rhodamine sulfonyl chloride and the chiral diamine (see Scheme 1) have been previously reported as a dark purple solid in a biphasic reaction of Os(II) arene complexes from in vivo toxicity in zebrafish (Danio rerio) embryos as a high-throughput vertebrate model, considered to be a predictor for drug toxicity in humans.

Unlike rodent models, zebrafish embryos are easy to handle, inexpensive, and useful for the study of solubilized compounds without consideration required for formulation or route of delivery. We investigated the MoA of the osmium(II) complexes in 2D cell culture and show how it translates into the in vivo zebrafish model. The zebrafish genome has been sequenced, and ca. 75% of human genes have at least one zebrafish orthologue.

Zebrafish embryos share developmental phenotypes with mammals, and many biochemical pathways are conserved. In fact, zebrafish have been used to identify cell cycle inhibitors and compounds that activate the p53 pathway, inducing apoptosis. Furthermore, the correlation between cardiotoxicity and hetotoxicity in zebrafish and preclinical mammalian models is well established.

Toxicity studies of Ru(II) and Ir(III) complexes in zebrafish have been reported, but this study appears to be the first on Os(II) complexes. We have synthesized a fluorescently labeled complex that has enabled the in vivo biodistribution of Os to be compared with the site(s) of ROS generation. This work reveals the critical roles of the ligands in determining the anticancer potency of complexes including their mechanism of action, toxicity, and selectivity and has allowed identification of complexes with potential for clinical development. Specifically, we investigate the translation of the mechanism of action and accumulation of Os(II) arene complexes from in vitro cellular studies to a readily available in vivo model.

**RESULTS**

Sulfonamide complexes 1–5 and 7–8 and azopyridine complexes 9–13 (Scheme 1) have been previously reported and are known to be stable in aqueous media. In addition, a novel rhodamine-conjugated sulfonamide-diphenyl-ethylenediamine ligand L6 was synthesized by the reaction between rhodamine sulfonyl chloride and the chiral diamine (see Supporting Information). Complex 6, containing ligand L6, was synthesized as a dark purple solid in a biphasic reaction (dichloromethane/water) with the dimer [η6-p-cymene)-OscL2]2 and a base (potassium hydroxide), yielding a dark purple solid.

**In Vitro Antiproliferative Activity.** Antiproliferative activities (IC50 values, concentrations that inhibit 50% of cell growth) toward nine human cancer cell lines were determined for complexes 1–13 by investigating cell viability after drug exposure (24 h + 72 h recovery time) using the SRB assay, and compared to the anticancer drug, cisplatin. The nature of the N,N-bidentate ligand is crucial to the anticancer activity in three parental cancer cell lines, A2780 (ovarian), A549 (lung), and HCT116 (colon), as can be seen in Tables S1 and S2. Sulfonamide complexes 1–8 have lower antiproliferative activity compared to cisplatin (IC50 4.4–30 μM in A2780, compared to 1.2 μM for cisplatin), while azopyridine complexes 9–13 were highly potent, achieving, in some cases, nanomolar potency (IC50 140 nM for 13 in A2780).

Generally, both series of Os(II) arene complexes were most potent toward A2780 ovarian cancer cells and least potent toward HCT116 colon cancer cells (Figure 1a, Table S1).

The η6-arene also influences the antiproliferative properties of the complexes, with higher activities achieved upon aren extension (p-cymene < biphenyl < m-terphenyl) in both the sulfonamide (2 < 7 < 8) and azopyridine (9 < 11; 10 < 12) series. This is probably due to increased hydrophobicity, although this does not always translate directly to increased cellular accumulation and improved anticancer potency since uptake mechanisms can involve active/energy-dependent pathways as well as passive diffusion. Nonetheless, the observed trend has been noted previously for other N,N'-chelated Os(II) arene “piano-stool” complexes. Furthermore, exchange of Cl for I in piano-stool azopyridine complexes 9–13 further enhanced the potency (9 < 10; 11 < 12), in some cases by nearly 2 orders of magnitude (in A549 cells: complex 11, IC50 20 ± 1 μM, compared to 12, IC50 0.27 ± 0.03 μM). Since halide exchange can modify cellular uptake and accumulation pathways involved in the first stages of drug action, such a potency increase by halide exchange may be attributed to the triggering of different apoptotic pathways as a consequence of differential compartmentalization and/or target recognition of the complexes once they have reached intracellular space.

In the clinic, ovarian cancers are commonly treated with platinum complexes, however, both intrinsic and acquired resistance mechanisms reduce the efficacy of platinum therapies. The ability of Os(II) arene complexes to circumvent Pt resistance mechanisms and maintain activity in Pt-resistant cell lines was first investigated using A2780 Cis (cisplatin-resistant) cancer cells. Resistance factors were determined as the ratio between IC50 values for Pt-resistant cells and parental cells (Figure 1b, Table S2), which provide an indication as to
whether it is possible for a given complex to maintain its potency in the platinum-resistant cell line. No reduction in potency was observed for any of the azopyridine complexes 9−13 in the Pt-resistant cell line, with the exception of chlorido complex 11 (3.9 ± 0.3 μM in A2780, 16.8 ± 0.2 μM in A2780 Cis). In the sulfonamide series, only complexes 3 and 4 maintained their antiproliferative potency in the Pt-resistant cell line (Figure 1b), showing that the nature of the N,N-chelating ligand, arene, and halide ligand all contribute to the overall biological properties of the complex. Azopyridine complexes 9−13 may have different uptake and efflux pathways compared to cisplatin and a mechanism of action that is not DNA-based.14

Further insights into the behavior of these Os(II) complexes at the cellular level can be gained by determination of osmium accumulation in the presence or absence of verapamil, a compound known to inhibit the transporter P-glycoprotein (PgP), which is associated with multidrug-resistant cells.40 Complex 1 appeared to undergo detoxification by PgP-promoted cellular efflux (P < 0.05), as well as complex 10 but to a lesser extent (see Supporting Information). This demonstrates how the bidentate ligand can affect cellular accumulation via biochemical interactions experienced by metal complexes in cells.

Pt-resistance at the cellular level is also related to the presence/absence of mutations in particular oncogenes, such as p21 and p53. Maintaining anticancer activity in cells with such mutations is particularly important since they are present in ca. 50% of cancers.41 The dependence of activity on the tumor suppressor P53 was investigated using HCT116p53−/− (P53 knockout) cancer cells (Table S2). While the P53 status affected some of the antiproliferative activities of the osmium complexes, the activity of some osmium azopyridine complexes was unaffected (complex 13: 0.15 ± 0.01 μM in the parental HCT116 cell line, compared to 0.13 ± 0.01 μM in p53−/− cells). For many of the azopyridine complexes, the significance was minor when compared to Pt drugs; cisplatin was almost an order of magnitude less active (36.7 μM) in the P53 knockout cell line. Similarly, dependence of activity on the tumor suppressor P21 was investigated in HCT116p21−/− (P21 knockout) cancer cells (Table S2). All complexes investigated (1−13 and cisplatin) showed lower activities in the P21 knockout cell line. Interestingly, in the case of HCT116Ox (oxaliplatin-resistant) colorectal cancer cells, both sulfonamide and azopyridine complexes all appeared to overcome Pt-resistance. In contrast, cisplatin was 4.5X less active in the Pt-resistant line. However, all osmium complexes were typically less active against the colorectal cancer cells (Figure 1a).

Antiproliferative activities in ovarian (A2780) and lung (A549) parental cancer cell lines were compared to data obtained in primary ovarian (HOF) and lung (MRC5) fibroblasts, models for noncancerous cells. Ratios between the anticancer activities in normal cells and cancer cells often provide an early indication of the possible therapeutic window for a given developmental drug, and the values are particularly relevant when compared to those of standards of care medications determined under the same experimental conditions. All Os(II) complexes typically showed good
selectivity between cells of ovarian origin, achieving up to 15× selectivity in the case of 10 (0.15 ± 0.01 μM in A2780 compared to 2.32 ± 0.01 μM in HOF), twice as selective as cisplatin (8.5×). In contrast, the anticancer selectivity between lung cells was much less apparent, ca. 4× for 10 (1.1 ± 0.2 μM in A549 compared to 4.5 ± 0.3 μM in MRC5), similar to cisplatin (Tables S1 and S2).

In Vitro Generation of Reactive Oxygen Species. Osmium azopyridine complexes have been shown to localize in the mitochondria of ovarian cancer cells using synchrotron X-ray fluorescence. Furthermore, investigations into their mechanism of action indicate that the generation of reactive oxygen species (ROS) in cancer cells is highly relevant to their anticancer activity. In particular, for complex 10 RNA-seq data shows time-dependent activation of cellular pathways that link the generation of ROS to the observed mechanism of action and subsequent cell death. We investigated the generation of reactive oxygen species (ROS) by sulfonamide complex 1 compared to azopyridine complexes 9 and 10. Although 1 is significantly less active than the azopyridine derivatives, all Os(II) complexes generated similar high levels of ROS and superoxide in A2780 human ovarian cancer cells upon exposure to equipotent drug concentrations (Figure 2 and Table S3).

We then investigated the generation of ROS in non-cancerous HOF human ovarian fibroblasts (Table S4). Interestingly, the generation of ROS was significantly lower than that observed in A2780 cancer cells for both Os(II) azopyridine and sulfonamide complexes. The Q2 population (superoxide and ROS) decreased from 96% to 38%, as we observed previously using MRC5 normal lung fibroblast cells exposed to 10. Normal cells are known to tolerate increased levels of oxidative stress better than cancer cells, and so selective generation of ROS in ovarian cancer cells can provide a novel targeted approach to chemotherapy, exploiting a key vulnerability of cancer cells.

Electrochemical Investigations of Osmium Azopyridine Complexes. Due to the clear involvement of ROS in the mechanism of action of complex 10, the electrochemical behavior of p-cymene complex 10 (red) and structurally
similar biphil complex 12 (blue) were studied by cyclic voltammetry (CV) using Ag/AgCl (0.21 V) as the reference electrode to determine ligand/metal based reduction potentials. The CVs of the two complexes (−2.0 V to +2.0 V; 100 mV/s; 10−3 M; CH3CN; see Figure S2) are in accordance with experimental CVs reported for structurally close arene osmium complexes.43 Both complexes 10 and 12, containing the strong π-acceptor ligand azpy, are reduced via two consecutive one-electron steps, with simultaneous loss of the halide ligand (Cl and I, respectively): The first reduction step (ca. −0.4 V) is electrochemically reversible (Figure 3b), with no loss of halide, whereas the second step is strongly dissociative with respect to the halide ligand. Thus, the redox mechanism of both complexes is an EEC mechanism (E, one-electron transfer at the electrode; C, chemical step, here, halide dissociation).

To investigate the redox behavior of both complexes in a biologically relevant range of potentials, CV spectra of 10 and 12 were monitored between −0.7 V and +0.7 V (Figure S3). Interestingly, for both complexes, the first one-electron step, without simultaneous loss of the halide ligand, is observed at a potential accessible for biological reductants. In this range of potentials, the absence of the second reduction wave allows the complexes to remain intact (no structural changes). This study suggests that ligand-centered redox processes of complexes 10 and 12 may be responsible for the ROS production in cancer cells. Further evidence of the link between ROS generation and the mechanism of action of complex 10 is its ability to produce OH radicals, which have been trapped using electron paramagnetic resonance (EPR) spectroscopy.44

Confocal Microscopy in Cancer Cells. To investigate cellular localization and further probe the mechanism of action, we synthesized a red-fluorescent Os(II) complex 6 (Figure 3a) derived from complex 1. Such a red fluorescent complex facilitates coinaging of complex localization (red) and ROS generation (using the green-fluorescent ROS detection reagent in flow cytometry studies, Figure 2). Previous work has shown that R2 substituents have little effect on the antiproliferative properties of complexes 1–5,13 and this was also the case for complex 6 (Figure 1). Optimal absorption and emission wavelengths for fluorescence studies were determined (ex/em = 560/580 nm, Figure 3b). Perhaps surprisingly, fluorescence was not quenched by Os in the complex, unlike in several previous reports of labeling transition metal complexes.45 Next, A2780 cancer cells were treated with red-fluorescent complex 6 (Figure 3a) and then stained with the green ROS-detection reagent (Enzo Life Sciences, Figure 3c) previously used in our flow cytometry investigations (Figure 2). The two emission bands were readily resolved, and clear colocalization (yellow) was observed between green (ROS production) and red (complex 6) fluorescence. These data provide validation of previous cellular metal accumulation studies using ICP-MS and ROS generation studied by flow cytometry. Moreover, these images further implicate ROS production as a major contributor to the mechanism of action of such Os(II) arene complexes.

In Vivo Toxicity Studies. Since the compounds showed promise in vitro, in vivo toxicities were investigated using zebrafish embryos, following the well-established zebrafish embryo toxicity (FET) test (Figure 4). Strikingly, the osmium complexes (1–13) were all less toxic, by up to 40× in the case of 10, toward zebrafish embryos compared to the anticancer drug cisplatin (LC50 = 0.6 ± 0.2 μM in SG-WT) in all three wild-type strains (AB, SG, and TU). Comparable activities were determined between wild-type embryos, suggesting that the origin of the strain selected for future study would not influence subsequent experimentation. A second-generation platinum anticancer drug carboplatin, was found to be an order of magnitude less toxic than cisplatin (LC50 = 5.7 ± 0.9 μM in SG-WT) toward zebrafish. The lower toxicity of carboplatin (especially nephrotoxicity, ototoxicity, and neurotoxicity) is well documented in human clinical trials. Interestingly, Os(II) azopyridine complexes were significantly less toxic than sulfonamide complexes, displaying low toxicity (LC50 = 24.3 ± 0.4 μM in the case of complex 10 against SG-WT embryos) in zebrafish (Figure 4 and Table S5).

In Vivo Generation of Reactive Oxygen Species: Does an in Vitro Mechanism of Action Translate to an in Vivo Animal Model? Since the in vitro mechanism of action of both Os(II) azopyridine and sulfonamide complexes appears to be strongly related to the generation of superoxide and ROS in cultured cancer cells, we investigated the translation of such mechanism of action to an in vivo model using zebrafish (Danio rerio) following an adapted literature procedure.46,47 Whole-mount zebrafish embryos were exposed to equitopotent solutions of Os(II) complexes 1 and 10 (1.0 × LC50) for 96 h and anaesthetized, then levels of reactive oxygen species were determined using a green fluorescent probe to detect ROS.

Figure 4. LC50 concentrations (μM) for osmium complexes 1–13 and Pt anticancer drugs (cisplatin and carboplatin) determined in three zebrafish (Danio rerio) embryo wild-type strains: Singapore (SG), Tubingen (TU), and AB-wild type. (a) Trends in acute toxicity are maintained in all three wild-type strains of zebrafish embryo. (b) All osmium arene complexes are less toxic (higher LC50) than CDDP. See Table S5 for full numerical data.
(including H$_2$O$_2$, peroxynitrite, and hydroxyl radicals) and analyzed using confocal microscopy.

Good dye localization was observed in the positive control (4 dpf zebrafish exposed to 50 $\mu$M rotenone for 5 min). Complexes 1 and 10 generated elevated levels of ROS in vivo in a concentration-dependent manner. ROS generated by treatment with Os-sulfonamide 1 appeared to locate largely in the swim bladder, whereas Os-azopyridine 10-generated ROS were more broadly distributed across the organism (Figure 5). Though the drug concentration was an order of magnitude less for 1 (2.4 $\mu$M compared to 24.3 $\mu$M), the levels of ROS appear qualitatively higher than in those treated with 10, which may be related to the radical induction efficiency.

Interestingly, complex 1 can catalyze transfer hydrogenation reactions in cells using formate as a hydride source, perturbing the cellular redox balance. Micromolar levels of formate are present in human serum, and while formate biochemistry in zebrafish is not fully understood, humans and zebrafish share similar one-carbon pathways. The catalytic properties of 1 may explain why ROS were present in qualitatively greater amounts, despite the administered concentration of 10 being an order of magnitude greater.

**Figure 5.** Reactive oxygen species (ROS) in anaesthetized whole-mount Singapore wild-type zebrafish (*Danio rerio*) treated with equipotent concentrations (1 or 2$\times$ LC$_{50}$) of Os-sulfonamide 1 or Os-azopyridine 10 for 96 h. Fluorescence for ROS (green) is shown superimposed onto bright field images. Embryos were stained using the green reagent of the ROS/Superoxide Detection Kit (Enzo life sciences) to detect ROS. Excitation, 458 and 488 nm; green emission for ROS, 493–550 nm. Rotenone was the positive control; 50 $\mu$M, 2 min exposure.

**Figure 6.** Two-color fluorescent imaging of whole mount SG-WT zebrafish (*Danio rerio*) treated with Os(II) sulfonamide 6 for 96 h. Fluorescence for ROS (green) and 6 (red) is shown superimposed onto bright field images. Overlapping regions (yellow) are shown. Confocal images were acquired using a Zeiss LSM880 confocal microscope. Embryos were stained using the green reagent of the ROS/Superoxide Detection Kit (Enzo life sciences) for ROS detection. Excitation, 458, 488, and 561 nm; green emission for ROS, 493–550 nm; red emission for 6, 568–750 nm. See SI for full confocal data.
Since ROS were highly localized in zebrafish treated with 1, we explored methods for determining local drug localization in vivo. Laser ablation coupled to inductively coupled plasma mass spectrometry (LA-ICP-MS), nanoscale secondary ion mass spectrometry (nanoSIMS) imaging, and electron microscopy have been explored for the detection of metal ions and nanoparticles in zebrafish. Confocal microscopy and fluorescent complex 6 provide an alternative strategy, which utilizes the transparent properties of zebrafish embryos. Zebrafish treated with red-fluorescent osmium complex 6 showed red fluorescence, indicative of in vivo complex localization. Remarkably, the in vivo distribution of ROS was similar to the internal localization of 6, as shown by the yellow areas (Figure 6), implicating the complex in the production of ROS. When taken with the statistically similar in vitro and in vivo activities of 1 and 6, it appears that the fluorescent marker had little influence on the biological interactions of the complex.

These studies confirm the high anticancer potency of osmium azopyridine complexes. Elevated levels of ROS were detected in A2780 cancer cells treated with nanomolar concentrations of 10 (Figure 2, Table S3); yet at micromolar concentrations, significantly lower levels were detected in noncancerous fibroblasts and in vivo in zebrafish (Table S4), despite the more than an order of magnitude higher dosage.

**DISCUSSION AND CONCLUSIONS**

Whereas half-sandwich osmium(II) arene azopyridine complexes can exhibit highly potent anticancer activity, sulfonamide complexes showed only moderate activity, highlighting the important role played by the N,N-bidentate ligand. In the cell lines investigated in this study, the osmium complexes exhibited highest potency against A2780 ovarian cancer cells, achieving nanomolar potency, compared to lower potency of previously reported Ru(II) analogues (IC50 2–6 μM, depending on azopyridine ligand and η6-arene). In the clinic, ovarian cancers are commonly treated with platinum anticancer complexes; however, both intrinsic and acquired resistance mechanisms reduce the efficacy of platinum-based therapies, highlighting the importance for the development of anticancer agents that operate by alternative mechanism(s) of action. Remarkably, azopyridine complexes 9–13 were found to circumvent cisplatin resistance, determined by comparing antiproliferative activities in A2780cis cisplatin-resistant cells compared to parental A2780 cells, and HCT116Ox oxaliplatin-resistant cells and parental HCT116 cells. In contrast, sulfonamide complexes appeared to share common resistance mechanisms with cisplatin, reflected by their lower potencies toward platinum-resistant cells compared to platinum-sensitive cells. The mechanisms of acquired resistance, particularly between A2780 and A2780 Cis resistant cells are well established. These include reduced cellular uptake and increased cellular efflux (both of which result in reduced cellular accumulation), as well as increased DNA repair. Hence, it is reasonable to hypothesize that azopyridine complexes 9–13 may have differences in uptake and efflux pathways compared to cisplatin and a mechanism of action, which is not DNA based, centered on ROS induction. Similarly, the P21/P53 status was not found to affect antiproliferative activities to the same extent as for cisplatin (over an order of magnitude activity decrease in the P53 knockout cell line). Maintaining anticancer activity in cell lines that have mutations in p53 is important, as it is well established that such a mutation is present in approximately 50% of all colorectal cancers. Clinical cases are prime examples of inherent platinum resistance. Taken together, these data suggest that the in vitro mechanism of action for Os-arene complexes, particularly for complexes bearing an azopyridine ligand, differs greatly from current platinum-based therapies and that they could be further developed to target both acquired and inherent platinum resistance.

The selective generation of reactive oxygen species in cancer cells has been suggested as a novel approach to chemotherapy, which exploits a key vulnerability of cancer cells. When exposed to either complex 1 [Os(p-cymene)-(TsDPEN)] or 10 [Os(p-cymene)(AzPy-NMe2)], in an equipotent manner, comparable levels of ROS/superoxide were detected in A2780 cancer cells (Table S1: 96 ± 1 and 95.4 ± 0.2%, respectively), indicative of a common mechanism of action for piano-stool osmium complexes involving redox modulation. However, in noncancerous ovarian fibroblasts, sulfonamide complex 1 generated significantly more ROS (FL1 channel) than azopyridine complex 10, suggesting that the nature of the N,N-bidentate ligand is crucial to the biological activity of the complexes and highlighting the efficacy of azopyridine complexes, which may exhibit fewer side effects if excessive ROS production is selective for cancer cells.

To confirm internalization of the osmium complex in vivo, fluorescent rhodamine complex 6 was synthesized and investigated in vivo using confocal microscopy. The localization of the complex in zebrafish embryos correlated well with oxidative stress, further implicating the involvement of the osmium complex in the production of ROS.

Elevated levels of ROS were detected in A2780 cancer cells treated with nanomolar concentrations of 10 (Figure 2, Table S3); yet at micromolar concentrations, significantly lower levels were detected in vitro using noncancerous fibroblasts and in vivo using zebrafish (Table S2), despite the more than an order of magnitude higher dosage. In these experiments, azopyridine complex 10 has shown clinical promise for the selective generation of oxidative stress in cancer cells over noncancerous cells and, to a lesser extent, in a whole organism model. Beyond using zebrafish as a toxicity model, future work might investigate the efficacy of complex 10 in tumor-bearing zebrafish since 10 has previously been shown to delay the growth of xenografts (HCT116 human colorectal cancer cells) in mice. In agreement with our findings using zebrafish, few toxic side effects were observed in the xenograft-bearing mice, reflected in a lack of clinical toxicity signs mice. Overall, it is apparent that the nature of the chelated ligand is highly influential over the biological properties of the complexes and crucially over the selective generation of reactive oxygen species in cancer cells compared to normal cells and living organisms. Determination of metallodrug speciation in a biological environment is crucial for further understanding of both the mechanism of action and the design of future metal-based anticancer agents.

**EXPERIMENTAL SECTION**

Materials. Osmium trichloride trihydrate was obtained from Heraeus South Africa Ltd. and Heraeus GmbH, (1R,2R)-Diphenylethylenediamine was purchased from Arran Chemical Company (Ireland). Ascorbic acid, carboplatin, cisplatin (CDDP), dimethyl sulfoxide (DMSO), sodium chloride, sulforhodamine B acid chloride, tricaine (4 mg·mL−1 tricaine powder in doubly deionized water, adjusted to pH 7 using Tris base), and thiourea were purchased from...
Sigma-Aldrich (UK). Magnesium sulfate, potassium hydroxide, and all nondried solvents were purchased from Fischer Scientific. Hanks Balanced Salt Solution (HBSS) was purchased from Scientific Lab Supplies. ROS/superoxide detection kit was purchased from Enzo Life Sciences (UK). Hoechst-33258 and Alexa Fluor 633 Phalloidin were purchased from ThermoFischer. Concentrated nitric acid (72% v/v) was freshly distilled before use. All reagents were used as received unless specified. Singapore wild-type (SG-WT) zebrafish were maintained in reverse-osmosis (RO) water supplemented with Aquavitro salt (pH 7.5). GEMMA micro powder food for zebrafish was purchased from Skretting. Live food (Artemia salina) was purchased from ZM Fish Food.

**Immunostaining.** Mass Spectrometry (HR-MS). Low resolution ESI-MS spectra for ligand L6 and complex 6 dissolved in acetonitrile were obtained using an Agilent 6130B ESI mass spectrometer. High resolution mass spectra were kindly acquired by Dr. L. Song and Mr. Phillip Aston using a Bruker UHR-Q-TOF MaXis, with a positive ion scan range of m/z 50–3000. Analysis was carried out through direct infusion (2 μL/min) with a syringe pump, with sodium formate (10 mM) calibration. Source conditions, ESI (+); end plate offset, 500 V; capillary, −3000 V; nebulizer gas (N2), 0.4 bar; dry gas (N2), 4 L/min; dry temperature, 453 K; funnel RF, 200 Vpp; multiple RF, 200 Vpp; quadrapole mass, 55 m/z; collision energy, 5.0 eV; collision RF, 600 Vpp; ion cooler RF, 50–250 Vpp ramping; transfer time, 121 μs; prepulse storage time, 1 μs.

**Elemental Analysis (CHN).** Elemental analysis for ligand L6 and complex 6 was carried out by Warwick Analytical Services UK on an Exeter elemental analyzer CE440.

**Nuclear Magnetic Resonance Spectroscopy (NMR).** Spectra for ligand L6 and complex 6 were acquired for CD3CN solutions in 5 mm NMR tubes (Sigma-Aldrich, UK).1H COSY, and 13C NMR spectra were recorded using a Bruker HD-500 NMR spectrometer using standard pulse sequences. Chemical shifts were referenced to residual solvent and processed using Topspin 3.2 (Bruker, UK).

**Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES).** Data were obtained using a PerkinElmer Optima 5300 DV Optical Emission Spectrophotometer, using a calibration range from 50 to 700 ppb, freshly prepared in 3.6% v/v nitric acid containing thiourea (10 mM) and ascorbic acid (100 mg/L) to stabilize osmium in nitric acid solution. Samples were diluted accordingly, and the salinity of the calibration adjusted to match the matrix of the samples by standard addition of sodium chloride solution. Os (λ = 225.585, 228.226 nm), Ir (λ = 208.882, 237.277 nm), and Pt (λ = 265.945, 204.937 nm).

**Inductively Coupled Plasma Mass Spectrometry (ICP-MS).** ICP-MS data were obtained using either an Agilent 7500 series or Agilent 5500 series ICP-MS with an internal standard of 166Er (50 ppb) in both no-gas and He-gas mode. Calibration standards for Os (0.1–1000 ppb) were freshly prepared in 3.6% v/v nitric acid containing thiourea (10 mM) and ascorbic acid (100 mg/L) to stabilize osmium in nitric acid solution. Data were acquired and processed using Agilent ChemStation for Windows (7500 series ICP-MS) or Agilent Mass Hunter 4.3 for Windows (7900 series ICP-MS).

**Three-Dimensional Fluorescence Spectroscopy.** Spectra for complex 6 (dissolved in acetonitrile, ~0.01 mM) were acquired using a Jasco FP-6500 Fluorimeter, with path length of 1 cm.

**Confocal Microscopy (Cancer Cells).** A2780 cancer cells treated with Os(II) complex 6 (0.5 × 1.0 × 1 cm) 24 h exposure were washed with PBS and stained using green ROX detection reagent (2 μM, Enzo Life Sciences). Cells were analyzed using a Zeiss LSM880 confocal microscope (Argon laser; excitation, 458, 488, and 561 nm; green emission for ROS, 493–550 nm; red emission for complex 6, 568–750 nm). Data were processed using Zen 2.3 for Windows.

**Confocal Microscopy (Zebrafish).** Whole-mount zebrafish were analyzed using a Zeiss LSM880 confocal microscope (Argon laser; excitation, 458, 488, and 561 nm; green emission for ROS, 493–550 nm; red emission for complex 6, 568–750 nm). Data were processed using Zen 2.3 for Windows.

**Chemical Synthesis.** The synthesis and full characterization of complexes 1–5 and 7–13 have been previously reported.10,21 The purity of all compounds determined by C, H, and N combustion elemental analysis was ≥95%.

2-(3-Diethylamino-6-diethylazaniumylidene-xanthen-9-yl)-5-(N-(2-aminio-1,2-diphenyl-ethyl)sulfonfonyl)-benzenesulfonate (Ligand L6). (1R,2R)-1,2-Diphenylethylenediamine (112 mg, 0.58 mmol, 1 mol equiv) and triethylamine (117 mg, 1.60 μL, 1.16 mmol, 2 mol equiv) were dissolved in dichloromethane (2 mL) at 273 K. Sulfurhidoxamine B acid chloride (400 mg, 0.69 mmol, 1.2 mol equiv) in dichloromethane (2 mL) was added dropwise over 3 h. The solution was washed with water (10 × 25 mL) and aqueous fractions extracted with dichloromethane (3 × 10 mL). Organic fractions were dried over magnesium sulfate, and the solvent was removed to yield a dark purple amorphous solid (78.6 mg, 0.104 mmol, 18%).1H NMR (500 MHz, CD3CN, 25 °C, TMS): δ = 8.43 (s, 1H, ArH), 7.49 (m, 1H, ArH), 7.38 (m, 1H, ArH), 6.88–7.35 (m, 1H, ArH), 6.81 (m, 2H, ArH), 4.55 (d, J(H,H) = 7.4 Hz, 1H, CHF2NH), 4.15 (d, J(H,H) = 7.4 Hz, 1H, CHNH), 3.58–3.73 (m, 8H, CH2), 1.24–1.33 (m, 12H, CH2).13C NMR (125 MHz, CD3CN, 25 °C, TMS) δ = 158.8, 158.4, 158.0, 139.6, 138.1, 137.4, 133.5, 133.6, 130.0, 128.6, 128.5, 128.3, 127.8, 127.6, 127.5, 127.4, 127.3, 127.0, 126.8, 113.6, 95.9, 65.1, 61.2, 60.2, 59.8, 50.0, 12.2. UV/vis: λmax 555, 399, 353, 307, 281, 258 nm. HRMS (m/z): [M + H]+ calcd. for C62H64N4O6S2: 1077.3329; found, 1077.3337. Analysis (calcd., found) for C62H64N4O6S2: C (65.40, 65.05), H (5.89, 6.04), N (7.44, 7.62). UV/vis: λmax 555, 399, 353, 307, 281, 258 nm. HRMS (m/z): [M + H]+ calcd. for C62H64N4O6S2: 1077.3329; found, 1077.3337. Analysis (calcd., found) for C62H64N4O6S2: C (65.40, 65.05), H (5.89, 6.04), N (7.44, 7.62).

**ASSOCIATED CONTENT**

Supporting Information The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.8b00958.

Experimental details regarding the in vitro and in vivo biological studies; numerical values for antiproliferative activity of complexes 1–13 and cisplatin in parental and resistant cancer cell lines; cell population percentages for the flow cytometry detection of ROS in A2780 cancer cell line and HOF human ovarian fibroblasts; LC50 concentrations in three zebrafish embryo wild-type strains; ROS detection in whole mount SG-WT zebrafish by confocal microscopy; cyclic voltammetry studies for complexes 10 and 12; inhibition of Pgp-mediated Os efflux by verapamil (PDP)

Molecular formulas strings (XLSX)
Acknowledgments

We thank EU COST Action CM1105 for stimulating discussions, Dr. R. Needham for the synthesis and characterization of azopyridine complexes, S. Heer for assistance with cell culture studies, Dr. V. Venkatesh for support with confocal microscopy, Miss S. Dixon and Dr. K. Sampath for guidance with zebrafish, Dr. L. Song and P. Aston for mass spectrometry, and Dr. I. Prokes for NMR spectroscopy. We also thank Heraeus GmbH for gifted osmium trichloride.

Abbreviations Used

AzPy, 2-phenylazopyridine; CDDP, cisplatin; IC50, half-maximal inhibitory concentration; LC50, half-maximal lethal concentration; PgP, P-glycoprotein; ROS, reactive oxygen species; SG-WT, Singapore wild-type (zebrafish); TsDPEN, N-tosyl-1,2-diphenylethylenediamine; TU-WT, Tubingen wild-type (zebrafish).

References

1. Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer statistics, 2016. Cancer Ca. 2016, 166 (1), 7–30.
2. Jemal, A.; Bray, F.; Center, M.; Ferlay, J.; Ward, E.; Forman, D. Global Cancer Statistics. Cancer Ca. 2011, 61 (2), 69–90.
3. Dasari, S.; Bernard Tchounouw, P. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 2014, 740, 364–378.
4. Chen, H. H. W.; Kuo, M. T. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met-Based Drugs 2010, 2010, 3070–3074.
5. Johnson, S. W.; Shen, D. W.; Pastan, I.; Gottesman, M. M.; Hamilton, T. C. Cross-resistance, cisplatin accumulation, and platinum–DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp. Cell Res. 1996, 226 (1), 133–139.
6. Köberle, B.; Tomicic, M. T.; Usanova, S.; Kaina, B. Cisplatin resistance: Preclinical findings and clinical implications. Biochem. Biophys. Acta, Rev. Cancer 2010, 1806 (2), 172–182.
7. Fu, Y.; Habtemariam, A.; Pizzaro, A. M.; van Rijt, S. H.; Healey, D. J.; Cooper, P. A.; Shnyder, S. D.; Clarkson, G. J.; Sadler, P. J. Organometallic osmium arene complexes with potent cancer cell cytotoxicity. J. Med. Chem. 2010, 53 (22), 8192–8196.
8. Shnyder, S. D.; Fu, Y.; Habtemariam, A.; van Rijt, S. H.; Cooper, P. A.; Loadman, P. M.; Sadler, P. J. Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex. MedChemComm 2011, 2 (7), 666–668.
9. Romero-Canelon, I.; Mos, M.; Sadler, P. J. Enhancement of selectivity of an organometallic anticancer agent by redox modulation. J. Med. Chem. 2015, 58 (19), 7874–7880.
10. Coverdale, J. P. C.; Romero-Canelon, I.; Sanchez-Cano, C.; Clarkson, G. J.; Habtemariam, A.; Wills, M.; Sadler, P. J. Asymmetric transfer hydrogenation by synthetic catalysts in cancer cells. Nat. Chem. 2018, 10, 347–354.
11. Hanif, M.; Babak, M. V.; Hartinger, C. G. Development of anticancer agents: wizardry with osmium. Drug Discovery Today 2014, 19 (10), 1640–1648.
12. Berger, G.; Grauwet, K.; Zhang, H.; Hussey, A.; Nowicki, M.; Wang, D.; Antonio Chiocca, E.; Lawler, S.; Lippard, S. J. Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models. Cancer Lett. 2017, 416, 138–148.
13. Suntharalingam, K.; Johnston, T. C.; Bruno, P. M.; Lin, W.; Hemann, M. T.; Lippard, S. J. Bidentate Ligands on Osmium(VI) Nitrido Complexes Control Intracellular Targeting and Cell Death Pathways. J. Am. Chem. Soc. 2013, 135 (38), 14060–14063.
14. Hearns, J. M.; Romero-Canelon, I.; Munro, A. F.; Fu, Y.; Pizzaro, A. M.; Garnett, M. J.; McDermott, U.; Carragher, N. O.; Sadler, P. J. Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2015, 112 (29), E3800–E3805.
15. Liou, G.-Y.; Storz, P. Reactive oxygen species in cancer. Free Radical Res. 2010, 44 (5), 479–496.
16. Queiroz, E. A. I. F.; Puukila, S.; Eichler, R.; Sampaio, S. C.; Forsyth, H. L.; Lees, S. J.; Barbosa, A. M.; Dekker, R. F. H.; Fortes, Z. B.; Khaper, N. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One 2014, 9 (5), e98207.
17. Wang, X.; Liu, J.; Jiang, L.; Wei, X.; Niu, C.; Wang, R.; Zhang, J.; Meng, D.; Yao, K. Bach1 induces endothelial cell apoptosis and cell-cycle arrest through ROS generation. Oxid. Med. Cell. Longevity 2016, 13.
18. Boonstra, J.; Post, J. A. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004, 337, 1–13.
19. Kim, S.-H.; Kim, K.-Y.; Yu, S.-N.; Park, S.-G.; Yu, H.-S.; Seo, Y.-K.; Ahn, S.-C. Monensin induces PC-3 prostate cancer cell apoptosis via ROS production and Ca2+ homeostasis disruption. Anticancer Res. 2016, 36 (11), 5835–5843.
20. Schumacker, P. T. Reactive oxygen species in cancer: a dance with the devil. Cancer Cell 2015, 27 (2), 156–157.
21. Fu, Y.; Romero, M. J.; Habtemariam, A.; Snowden, M. E.; Song, L.; Clarkson, G. J.; Qamar, B.; Pizzaro, A. M.; Unwin, P. R.; Sadler, P. J. The contrasting chemical reactivity of potent isoelectronic iminopyridine and azopyridine osmium(II) arene anticancer complexes. Chem. Sci. 2012, 3 (8), 2485–2494.
22. Bowman, T. V.; Zon, L. I. Swimming into the future of drug discovery: in vivo chemical screens in zebrafish. ACS Chem. Biol. 2010, 5 (2), 159–161.
23. Tan, J. L.; Zon, L. I., Chapter 21 - Chemical screening in zebrafish for novel biological and therapeutic discovery. In Methods in Cell Biology, William, H., Detrich, M. W., Leonard, I. Z., Eds.; Academic Press: 2011; Vol. 105, pp 491–516.
(24) Eimon, P. M.; Rubinstein, A. L. The use of in vivo zebrafish assays in drug toxicity screening. Expert Opin. Drug Metab. Toxicol. 2009, 5 (4), 393–401.
(25) Renneckam, A. J.; Peterson, R. T. 15 years of zebrafish chemical screening. Curr. Opin. Chem. Biol. 2015, 24, 58–70.
(26) Barbazuk, W. B.; Korf, I.; Kadavi, C.; Heyen, J.; Tate, S.; Wun, E.; Bedell, J. A.; McPherson, J. D.; Johnson, S. L. The synergetic relationship of the zebrafish and human genomes. Genome Res. 2000, 10 (9), 1351–1358.
(27) Sipes, N. S.; Padilla, S.; Knudsen, T. B. Zebrafish—As an integrative model for twenty-first century toxicity testing. Birth Defects Res., Part C 2011, 93 (3), 256–267.
(28) Murphy, R. D.; Stern, H. M.; Straub, C. T.; Zon, L. I. A chemical genetic screen for cell cycle inhibitors in zebrafish embryos. Chem. Biol. Drug Des. 2006, 68 (4), 213–219.
(29) Li, Y.; Huang, W.; Huang, S.; Du, J.; Huang, C. Screening of anti-cancer agent using zebrafish: comparison with the MTT assay. Biochem. Biophys. Res. Commun. 2012, 422 (1), 85–90.
(30) MacRae, C. A.; Petersen, R. T. Zebrafish as tools for drug discovery. Nat. Rev. Drug Discovery 2015, 14 (10), 721–731.
(31) Alfaro, J. M.; Prades, A.; del Carmen Ramos, M.; Peris, E.; Ripoll-Gómez, J.; Poyatos, M.; Burgos, J. S. Biomedical properties of a series of ruthenium-N-heterocyclic carbene complexes based on oxidant activity in vitro and assessment in vivo of biosafety in zebrafish embryos. Zebrafish 2010, 7 (1), 13–21.
(32) Lesin-Rojas, O. A.; Fernandes, A. R.; Roma-Rodrigues, C.; Baptista, P. V.; Marques, F.; Perez-Fernandez, D.; Guerra-Varela, J.; Sanchez, L.; Vasquez-Garcia, D.; Torres, M. L.; Fernandez, A.; Fernandez, J. J. Heteroleptic mononuclear compounds of ruthenium(II): synthesis, structural analyses, in vitro antitumor activity and in vivo toxicity on zebrafish embryos. Dalton Trans. 2016, 45 (47), 19127–19140.
(33) Tang, T. S.-M.; Leung, K.-K.; Louie, M.-W.; Liu, H.-W.; Cheng, S. H.; Lo, K. K.-W. Phosphorescent biscyclometallated iridium(III) ethenylendiamine complexes functionalised with polar ester or carboxylate groups as bioimaging and visualisation reagents. Dalton Trans. 2015, 44 (11), 4945–4956.
(34) Li, S. P.-Y.; Lau, C. T.-S.; Louie, M.-W.; Lam, Y.-W.; Cheng, S. H.; Lo, K. K.-W. Mitochondria-targeting cyclometalated iridium(III)–PEG complexes with tunable photodynamic activity. Biomater. 2013, 34 (30), 7519–7532.
(35) Lui, Z.; Habtemariam, A.; Pizarro, A. M.; Fletcher, S. A.; Kisova, A.; Vrana, O.; Salassa, L.; Bruijninckx, P. C. A.; Clarkson, G. J.; Brabec, V.; Sadler, P. J. Organometallic half-sandwich iridium anticancer complexes. J. Med. Chem. 2011, 54 (8), 3011–3026.
(36) Romero-Canelón, I.; Salassa, L.; Sadler, P. J. The contrasting activity of iodido versus chlorido ruthenium and osmium arene azobispyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway. J. Med. Chem. 2013, 56 (3), 1291–1300.
(37) Tees, D.; Huber, L. A. The odd couple: signal transduction and endocytosis. Cell. Mol. Life Sci. 2003, 60 (10), 2020–2033.
(38) Sanchez-Cano, C.; Romero-Canelón, I.; Yang, Y.; Hands-Portman, I. J.; Bohic, S.; Cloetens, P.; Sadler, P. J. Synchrotron x-ray fluorescence nanoprobe reveals target sites for organo-osmium complex in human ovarian cancer cells. Chem. – Eur. J. 2017, 23 (11), 2512–2516.
(39) Alberts, D. S. Carboplatin versus cisplatin in ovarian cancer. Semin Oncol. 1995, 22 (5), 88–90.
(40) Nanayakkara, A. K.; Pollit, C. A.; Chen, G.; Williams, N. S.; Vogel, P. D.; Wise, J. G. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Sci. Rep. 2018, 8 (1), 967.
(41) Ozaki, T.; Nakagawara, A. Role of p53 in cell death and human cancers. Cancers 2011, 3 (1), 994–1013.
(42) Hileman, E. O.; Liu, J.; Albitar, M.; Keating, M. J.; Huang, P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother. Pharmacol. 2004, 53 (3), 209–219.